Hunan Dajiaweikang Pharmaceutical IndustryLtd Past Earnings Performance
Past criteria checks 4/6
Hunan Dajiaweikang Pharmaceutical IndustryLtd's earnings have been declining at an average annual rate of -23.3%, while the Healthcare industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 22% per year. Hunan Dajiaweikang Pharmaceutical IndustryLtd's return on equity is 3%, and it has net margins of 1%.
Key information
-23.3%
Earnings growth rate
-31.6%
EPS growth rate
| Healthcare Industry Growth | 7.0% |
| Revenue growth rate | 22.0% |
| Return on equity | 3.0% |
| Net Margin | 1.0% |
| Next Earnings Update | 30 Oct 2024 |
Recent past performance updates
Recent updates
There's Reason For Concern Over Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Massive 41% Price Jump
Oct 08
Optimistic Investors Push Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Shares Up 30% But Growth Is Lacking
May 09Market Might Still Lack Some Conviction On Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Even After 31% Share Price Boost
Mar 08Revenue & Expenses Breakdown
How Hunan Dajiaweikang Pharmaceutical IndustryLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4,734 | 48 | 645 | 14 |
| 31 Mar 24 | 4,307 | 38 | 542 | 9 |
| 31 Dec 23 | 3,904 | 34 | 436 | 7 |
| 30 Sep 23 | 3,830 | 22 | 384 | 4 |
| 30 Jun 23 | 3,666 | 31 | 361 | 2 |
| 31 Mar 23 | 3,542 | 47 | 314 | 1 |
| 01 Jan 23 | 3,292 | 51 | 271 | 1 |
| 30 Sep 22 | 2,943 | 71 | 221 | 0 |
| 30 Jun 22 | 2,733 | 71 | 184 | 0 |
| 31 Mar 22 | 2,643 | 68 | 175 | 0 |
| 31 Dec 21 | 2,592 | 68 | 162 | 0 |
| 30 Sep 21 | 2,536 | 85 | 252 | 0 |
| 30 Jun 21 | 2,535 | 89 | 133 | 0 |
| 31 Mar 21 | 2,387 | 79 | 132 | 0 |
| 31 Dec 20 | 2,340 | 65 | 137 | 0 |
| 31 Dec 19 | 2,457 | 88 | 126 | 0 |
| 31 Dec 18 | 2,189 | 78 | 125 | 0 |
| 31 Dec 17 | 2,022 | 80 | 126 | 0 |
| 30 Jun 17 | 2,003 | 65 | 111 | 0 |
| 31 Mar 17 | 1,951 | 61 | 101 | 0 |
| 31 Dec 16 | 1,899 | 58 | 91 | 0 |
| 30 Sep 16 | 1,787 | 54 | 78 | 0 |
| 30 Jun 16 | 1,674 | 50 | 66 | 0 |
| 31 Mar 16 | 1,605 | 49 | 63 | 0 |
| 31 Dec 15 | 1,537 | 47 | 61 | 0 |
| 30 Sep 15 | 1,879 | 44 | 78 | 0 |
| 30 Jun 15 | 2,221 | 40 | 95 | 0 |
| 31 Mar 15 | 1,905 | 31 | 82 | 0 |
| 31 Dec 14 | 1,588 | 21 | 69 | 0 |
| 31 Dec 13 | 154 | 3 | 10 | 0 |
Quality Earnings: 301126 has high quality earnings.
Growing Profit Margin: 301126's current net profit margins (1%) are higher than last year (0.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 301126's earnings have declined by 23.3% per year over the past 5 years.
Accelerating Growth: 301126's earnings growth over the past year (54.4%) exceeds its 5-year average (-23.3% per year).
Earnings vs Industry: 301126 earnings growth over the past year (54.4%) exceeded the Healthcare industry -6.3%.
Return on Equity
High ROE: 301126's Return on Equity (3%) is considered low.